Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for April 24, 2008 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



BII Noida introduces Advance Program in Clinical Trials
BII Noida is happy to introduce 9 months weekend Advance Program in Clinical Trials.The main objective of the course is to provide students with a theoretical and practical understanding of the issues involved in the design, conduct, analysis and interpretation of Clinical trials. 
x-small text small text medium text large text


    /24-7PressRelease/ - NOIDA, INDIA, April 24, 2008 - Bioinformatics Institute of India is happy to introduce 9 months weekend Advance Program in Clinical Trials. The main objective of the course is to provide students with a theoretical and practical understanding of the issues involved in the design, conduct, analysis and interpretation of clinical trials.

Program Methodology

• Prospective participants may join the program by submitting the application form along with the necessary Fees and attachments.

• Lecture classes for the program would be taken by expertise faculty

• Guest faculty from industry and academia would also deliver the lecture

• Students would be taken for Clinical site visits to various hospitals etc.

• Along with the regular classes students would also be provided with the practical industry oriented knowledge of the subject .

• E-learning platform via Moodle would also be provided to students


Program Duration
The Program Duration is 9 months.

Program Eligibility
The eligibility for the training program is graduation in any discipline. Highly interested participants in final year can also apply. The course is most suitable for Doctors, Medical professionals, pharmacist etc. Program details are available at http://www.bii.in

Program Fees
The Program fees is Rs.35, 000/-. Payment can also be made in installments.

Career Prospects:
Excellent career opportunities exist for students and professionals who are trained in these areas. Placement support is provided.

Bioinformatics Institute of India (BII) is the pioneer in the field of Bioinformatics and is today recognized across the globe as a premier institution offering programs in the area of Bioinformatics, Clinical Trials, Pharma Regulatory affairs, Pharma Quality Assurance and Control, Drug Design and Patenting, IPR and Biotechnology etc. BII is proud to have thousand of participants from more than 40 countries in these programs. We offer these training programs through various modes including distance participation, e-learning, classroom etc. We are also proud to supply multimedia and corporate training kits to governments, private bodies and individuals in our areas of expertise. BII is the biggest training organization in its field in India.

How to join: For a free copy of the prospectus email/write to the
Bioinformatics Institute of India
C-56 A/28, Sector 62
Noida
Tel: 0120-4320801, 802, 9810535368
http://www.bii.in, biinoida@gmail.com
info@bii.in, support@bioinformaticscentre.org


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #


Read more Press Releases from Charu agarwal:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Charu agarwal
Bioinformatics Institute of Indi

BII Noida
C-56A/28, Sec-62
Noida, U.P
India
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.